FIELD: biotechnology.
SUBSTANCE: invention relates to peptidic agonists of type II angiotensin II (AT2R) receptor, and can be used for treating diabetes, cardiovascular diseases, metabolic syndrome and hypertension. Disclosed are pharmaceutical compositions based on a polypeptide of formula: A1-A2-A3-A4-A5-A6, where: A1 is Lys, A2 is Pro, 3Hyp or 4Hyp, A3 is Leu or Ile, A4 is Lys, A5 is Pro, 3Hyp or 4Hyp and A6 is Trp.
EFFECT: invention provides effective treatment of diseases characterized by insufficient activity of AT2R or excessive activity of angiotensin II type 1 receptor (AT1R).
4 cl, 4 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE | 2011 |
|
RU2754957C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF GASTROINTESTINAL DISORDERS | 2014 |
|
RU2763796C2 |
